Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nitrosomonas eutropha
- Development stage
- Phase 1
- Lead developer
- AOBiome LLC
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Topical, Intranasal
01
Overview
**Nitrosomonas eutropha** is a live topical microbiome therapeutic based on a single strain of ammonia-oxidizing bacteria being developed by AOBiome for inflammatory skin diseases. Public company materials describe the clinical candidate as **B244**, a purified topical preparation of *Nitrosomonas eutropha* intended to repopulate the skin microbiome and modulate inflammation. Its proposed biology is that ammonia oxidation generates nitric oxide and related metabolites and downregulates type 2 inflammatory signaling, with company materials highlighting effects on IL-4, IL-5, IL-13, and IL-31, and publications noting suppression of T helper 2 polarization through IL-10. Clinical and translational work has linked this organism/product to development in acne vulgaris, atopic dermatitis, eczema, rosacea, allergic rhinitis, migraine, and hypertension, although the clearest publicly documented dermatology development is topical use in acne and atopic dermatitis.
- Other names
- Nitrosomonas eutrophaammonia-oxidizing bacteriaAOB
Beyond the preview
Go deeper on Nitrosomonas eutropha.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nitrosomonas eutropha.